Dec 08,2022

Better Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline Results

Better Therapeutics today announced positive results of the first-ever study evaluating the feasibility of using a prescription digital therapeutic to reduce liver fat and improve liver disease biomarkers in Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). The study included a cohort of 22 patients with NAFLD and NASH and used Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF) scans, a validated proxy for liver biopsies, to monitor changes in liver fat. The study relied on Better Therapeutics’ CBT platform, which has been developed with the intention of helping patients with cardiometabolic diseases – including NASH and NAFLD – access a tailored treatment that leverages CBT techniques to address underlying causes of these diseases and help them make sustainable behavioral changes.

CLINICAL STUDY

#pdt

#cbt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 13,2022

A New Study From Hello Heart Shows Surprising Findings on Walking Patterns and Heart Health

Hello Heart today announced new data on how minor lifestyle and behavioral changes can have a significant impact on improving heart health. The findings were collected from 6,000 Hello Heart users nationwide over six months. According to this new data, it’s not as daunting to make a positive impact on systolic blood pressure as people may think.

CLINICAL STUDY

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Dec 15,2022

Pear Therapeutics Presents Real-World Clinical Data Assessing Engagement And Abstinence In Patients With Alcohol Use Disorders Using ReSET At AAAP

Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced data from a real-world analysis of engagement, substance use, and retention patterns in patients diagnosed with substance use disorder who use alcohol and were treated with reSET. The real-world observational study evaluated 548 patients with alcohol-related disorders from 28 states who were treated with reSET over 12 weeks. The primary endpoint was engagement with reSET (lessons completed) throughout the prescription, and activity was also assessed as any use of reSET during a given week. Highlights presented include. Highlights presented include 9.7% of patients (n=548) were retained in treatment during weeks 9-12 (last 4 weeks).

CLINICAL STUDY

#pdt

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 19,2022

New Research Published in Peer Reviewed Journal Demonstrating Dario's Musculoskeletal Solution Reduces Back Pain

DarioHealth Corp. announced the publication of a new study in the peer-reviewed journal Frontiers in Physiology today demonstrating the effectiveness of the Company's musculoskeletal solution, which uses real-time biofeedback and behavior training to reduce back pain. The new research used retrospective data from 981 users engaged with Dario Move's posture trainer for at least eight weeks to examine the relationship between the amount of time spent training, the use of the device and reduction in back pain levels. The study examined the user's data after eight weeks of training and found significant clinical impacts Users experienced an average 50% reduction in pain.

CLINICAL STUDY

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Jan 15,2020

Akili Interactive: Digital pediatric ADHD therapeutic performs well with or without accompanying stimulant therapy

Digital therapeutic company Akili Interactive has announced the first results of an open-label, multisite pediatric ADHD trial providing some patients with the company’s video game-like treatment alongside a stimulant medication. Called the STARS-ADHD Adjunctive trial, these data further build upon pivotal study data supporting AKL-T01 (Project: Evo) that was reported by the company in late 2017

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 13,2020

Omada Program Achieves Key Results with Underserved Populations

A recent study shows the Omada Diabetes Prevention program can deliver meaningful engagement and clinical outcomes for underserved populations. The trial, published in Preventing Chronic Disease, tracked 227 individuals who enrolled in Omada’s adapted Program for Underserved Populations. Participants in the study averaged more than four percent weight loss one year after beginning the program. The program also achieved strong engagement, with more than half of participants completing the DPP program.

CLINICAL STUDY

#coaching

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 24,2020

Akili Announces Publication of AKL-T01 ADHD Pivotal Study Results in the Lancet Digital Health

Akili Interactive today announced that results from the STARS-ADHD trial of AKL-T01, a digital therapeutic designed to improve attention in children with attention-deficit/hyperactivity disorder (ADHD) were published in The Lancet Digital Health journal. In the study of 348 children diagnosed with ADHD, AKL-T01 showed improvements across a wide range of attention measures, from objective measures of attention to how attention impacted daily life and functioning. AKL-T01 showed a statistically significant improvement compared to an educational-style video game control on the predefined primary endpoint, a change in the Attention Performance Index (API) of the Test of Variables of Attention (TOVA®).

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Feb 25,2020

One Drop Increases Accuracy of AI-powered Hypoglycemia and Hyperglycemia Predictions and Introduces Alert Capability for People Using CGMs

One Drop, a leader in digital therapeutics solutions for people living with diabetes and other chronic conditions, presented new results for continuous glucose monitor-based glucose predictions at The 13th International Conference on Advanced Technologies & Treatments for Diabetes. One Drop’s patent-pending machine learning model accurately predicts the probabilities that a user’s glucose will rise above 180 mg/dL or fall below 70 mg/dL. At 30 minutes, the predictions are 99.5% accurate, at 1 hour, 98.6% accurate, and at 4 hours, One Drop’s accuracy is 91.9%

CLINICAL STUDY

#cgm

#mobile app

#software

View Analyst & Ambassador Comments
Go to original news
Feb 28,2020

Helping low-income students take control of asthma: A Q&A with Dr. Theresa

Children with asthma in low-income areas experience significantly greater healthcare utilization than children in high-income areas. Dr. Theresa Guilbert, a pediatric pulmonologist and director of the Asthma Center at Cincinnati Children’s Hospital, works closely on this issue. She and her team recently completed a first-of-its-kind study, which combined telehealth, in-person visits and Propeller’s digital health platform to help economically disadvantaged students in Cincinnati take control of their asthma. Students received Propeller sensors for their inhalers and used our smartphone app to manage their medication regimen. The study’s outcomes are promising. In six months, the students improved their controller medication adherence by up to 46% and experienced no emergency department visits or hospitalizations — a significant improvement over baseline.

CLINICAL STUDY

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Mar 04,2020

Better Therapeutics to Present Phase 2 Data in Type 2 Diabetes at Endocrine 2020

Better Therapeutics, a developer of prescription digital therapeutics for the treatment of cardiometabolic diseases, today announced an upcoming poster presentation at the Endocrine 2020 conference. The presentation will include data from a pilot study of Better’s software-only prescription digital therapeutic in patients with type 2 diabetes. A study abstract of preliminary results has been included in the conference guide, and will be published in the Journal of the Endocrine Society and on the Better Therapeutics website later this month. Highlights of the pilot study include: Mean reduction in fasting blood glucose of 21.9 mg/dL (approximately -1.0% HbA1c) over an average of 73 days between baseline and ending values. Next, the company will conduct an open-label, multi-site, randomized, controlled, parallel-group trial of its digital therapeutic for treating type 2 diabetes and submit the results as the basis of its premarket submission to the U.S. Food and Drug Administration (FDA).

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY